STRATEGIC NEWS WATCH — September 10, 2026
|
Bayer’s Hyrnuo reached first-line HER2-mutant lung cancer seven months behind Boehringer’s rival and still without survival data, while in China Novo Nordisk’s Wegovy became the first GLP-1 approved for MASH — a landmark clearance whose regulatory pathway, covered fibrosis stages and pricing were all left undisclosed. Today’s top developments:
|
What to Watch
- SOHO-02 is the real event — Bayer’s frontline label rests on a 75% response rate with no survival data, and Boehringer’s Hernexeos reached the same indication in February 2026 on the same basis. The confirmatory SOHO-02 comparison against standard of care (NCT06452277), and any comparative data either sponsor generates, will decide more than Bayer’s label — right now nothing separates the two agents.
- China’s Wegovy label and reimbursement — The pathway, the fibrosis stages covered and any pricing arrangement went undisclosed. The label wording — and whether the indication enters China’s national reimbursement drug list — will determine whether the approval is commercially meaningful in the market where MASH epidemiology is largest.
- Biohaven’s nonclinical package — The hold is partial, so the fully enrolled pivotal study continues on schedule. How quickly Biohaven delivers the rodent-metabolite risk assessment, and whether SK Biopharmaceuticals closes the transaction on the original terms after paying $350 million up front, are the open questions.
- Qulipta’s filing and the trial size — AbbVie has named no submission date and no congress for the detailed Luna results, and the study’s enrolment was not disclosed. Both matter, because a 0.8-day placebo-adjusted difference reads very differently depending on the N behind it.
- Whether other Novartis holders join — Samra is one voice among the top 20. Whether other institutional investors align before the next annual meeting is the near-term signal, along with whether Novartis changes how it runs diligence rather than only defending its capital-allocation record.
This brief highlights the edition’s top stories. Read the full September 10, 2026 edition → for all stories and analysis — or browse the Strategic News Watch archive.